Phase II trial Combining Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer

Dr. Yang-Min Ning and collaborators reported, in the April 20, 2010 issue of the Journal of Clinical Oncology, a Phase II trial which combined chemotherapy (docetaxel) with an anti-angiogenesis drug for men with castration-resistant prostate cancer (CRPC). The data suggests that such a combination is more effective than chemotherapy alone. […]

Lenalidomide in Combination with Docetaxel to Treat Advanced Prostate Cancer

More from my explorations at the American Association of Cancer Researchers (AACR) conference in Washington, D.C. Abstract 5386 described a study using a thalidomide analogue called lenalidomide (Revlimid), in combination with Taxotere, which currently is the only approved drug for chemotherapy for advanced, metastatic castrate resistant prostate cancer. […]

Chemotherapy, Combining Drugs to Extend Life

The continuing search for effective treatments for men with hormone refractory prostate cancer (HRPC) has been a long and not very successful story. To date, under scientific conditions, the only chemotherapy which has demonstrated any survival benefit for men with prostate cancer has been docetaxel with prednisone. However, the survival benefit is very limited, only 2.5 months. It has not been for the lack of trials, but to date researchers have not been able to find any other drug that works, that extends the life of men with HRPC. Various investigation drugs have been tried, but none have demonstrated any additional survival benefit. Some researchers have expanded their work to evaluate the potential of combining different drugs in combination, not dissimilar to the cocktails that have been successful in controlling AIDS/HIV. […]


According to a randomized study from the National Cancer Institute published online January 23, 2009 in the Journal of Urology (Vol. 181, pp.1104-13), Thalidomide may be effective for the treatment of men who have experienced a biochemical recurrence of prostate cancer (a rise in their PSA) after receiving and failing another primary treatment.  This study was run and reported by William D.Figg, PharmD, head of the Molecular Pharmacology Section of the Centerfor Cancer Research at the National Cancer Institute, in Bethesda, MD. In the late 1950s and early 1960s, more than 10,000 children in 46 countries were born with significant deformities as a consequence of thalidomide use by their pregnant mothers.  Because of these startling deformities doctors stopped perscribing it, Thalidomide almost became a lost drug. Today, researchers have rediscovered Thalidomide and started investigating it for treating symptoms of prostate cancer, glioblastoma, lymphoma, arachnoiditis, Behçet’s disease, and Crohn’s disease.  In a small trial, Australian researchers found thalidomide sparked a doubling of the number of T cells in patients, allowing the patients’ own immune system to attack cancer cells.  Additionally,  Thalidomide inhibits the growth of new blood vessels (angiogenesis) which are required by tumors to grow as well as working as a potent anti-inflammatory. […]